Caribou's Allogeneic CAR-T Data Rivals Autologous Therapies; Q2 Results Show Cash Runway
CRBU sits 17% above its 52-week low of $1.38.
Summary
Caribou reported Q2 2026 results alongside detailed EHA 2026 data for its two lead allogeneic CAR-T programs. Vispa-cel in 2L LBCL showed 82% ORR, 67% CR, and 17.1-month median PFS in the optimized subgroup (N=27), which the company says is on par with approved autologous therapies. CB-011 in r/r MM showed 92% ORR and 83% ≥CR in BCMA-naïve patients at the RDE, with 50% still in ≥CR at 15 months. The company also highlighted a case study of a heavily pretreated patient achieving CR after a single CB-011 dose. Financially, Caribou reported licensing revenue and reiterated a 12-month operating runway from the prior quarter. This follows the June 11 positive Phase 1 data release and adds granular efficacy numbers plus financials. The key upcoming catalyst is H2 2026 dose expansion data for CB-011 in >15 patients with ≥3 months follow-up.
At the time of this announcement, CRBU was trading at $1.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159.7M. The 52-week trading range was $1.38 to $3.54. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.